MRNA Short Squeeze Score: 22 / 100
// MRNA ranked on Tapeboard's 0-100 short squeeze leaderboard · components disclosed below · methodology fully published
This score isn't static — short interest re-settles every two weeks and MRNA's borrow fee can spike intraday. Tapeboard re-scores MRNA every day, ranks it against the full live squeeze board, and pairs it with a real-time scanner and watchlist — so you catch the setup changing, not a snapshot. Free, no card.
How MRNA got to 22 / 100
The MRNA squeeze score is a weighted sum of seven normalized components, short interest as a percentage of float, IBKR borrow fee, float utilization, FINRA CNMS daily short-volume ratio, days to cover, trailing 5-day price momentum, and the borrow fee's 5-day change. Each component is z-scored against a universe of roughly 500 active US equities, then combined with the weights shown below.
// component breakdown not available, squeeze ingest pending. The leaderboard refreshes after FINRA settlement files post (typically 9 PM ET).
What's moving MRNA right now
What's moving the tape on MRNA, grounded in Tapeboard's data. Not investment advice.
As of
- Moderna To Present Additional Data From Key Melanoma Trial At ESMO Congress – Retail Says ‘Breakout Is Getting Hard To Ignore’ (Yahoo) - Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher (Yahoo)
- Phase 3 melanoma data for intismeran autogene secured a Presidential Symposium slot at ESMO 2026, signaling strong clinical interest. - Recent earnings surprises have been positive (e.g., Q2 2026 EPS beat estimate by 7.3%), indicating improving profitability trends.
- Revenue fell 39.9% YoY to $1.94B in FY 2025, reflecting a sharp decline from prior‑year levels. - Net income remains deeply negative at –$2.82B for FY 2025, with ongoing operating cash‑flow deficits.
- Persistent net losses and negative operating cash flow raise concerns about cash runway despite a $2.6B cash balance. - Valuation metrics are elevated (P/S ~31.7, P/B ~10.4) relative to peers, leaving little margin for error if trial results disappoint.
- The ultimate regulatory and commercial success of intismeran autogene beyond the melanoma trial is not yet known. - How competitors’ mRNA cancer vaccines (e.g., Merck/BioNTech) will affect Moderna’s market share remains uncertain. --- This is an automated summary of publicly available data, not financial advice. It is for informational purposes only — nothing here is a recommendation to buy or sell any security. Do your own research and consult a licensed financial advisor before making investment decisions.
MRNA 30-day borrow fee and short interest trend
Trailing-30-day series of two of the highest-signal squeeze inputs for MRNA, the IBKR borrow fee (cost to short the stock) and short interest as a percentage of float. Free per-ticker borrow-fee history is not published by Fintel or Ortex on their public pages.
// daily snapshots · L=30d low · H=30d high · borrow fee from IBKR Stock Loan Availability · SI %Float from FINRA settlement files (bi-monthly, ~10 day delay)
How the score is calculated
Tapeboard's short squeeze score (v2) weights short interest at 25%, borrow fee at 20%, float utilization at 15%, daily short-volume ratio at 15%, days to cover at 10%, 5-day momentum at 10%, and borrow-fee 5-day change at 5%. Sources: FINRA bi-monthly settlement data for short interest, IBKR Stock Loan Availability for borrow fees and utilization, FINRA CNMS daily short sale volume files for the daily short-volume ratio, and FINRA Threshold Securities List for the failures-to-deliver flag. Full methodology, including normalization formula, known limitations, and the reasoning behind each weight, is published at /methodology/short-squeeze-score.
// other tickers high on the squeeze leaderboard:
Frequently asked questions about MRNA squeeze risk
What does a Short Squeeze Score of 22 / 100 mean for MRNA?
A score of 22/100 for MRNA indicates the structural squeeze conditions are weak today. That can change fast, short interest reports settle bi-monthly, and borrow fees can spike intraday on adverse news.
How fresh is the MRNA squeeze data?
MRNA's score recomputes once daily after the US market close (typically by 9 PM ET). Borrow fee, float utilization, and momentum refresh daily and are live. Short interest carries the most recent FINRA settlement date and is held between readings, because FINRA publishes short interest on a settlement schedule, not daily. That is why the SI %Float row above is stamped with its own as-of date. Real-time short interest does not exist publicly in US markets.
Is MRNA on the FINRA threshold list?
As of the most recent FINRA file, MRNA is not on the threshold list. The list is published end-of-day and a ticker can move on or off based on cumulative settlement failures over rolling five-day windows. See stocks currently on the threshold list.
Track MRNA's squeeze setup as it moves.
Re-scored daily, ranked against the full live squeeze board, with 30-day borrow-fee and short-interest history and a real-time scanner beside it. 28 seconds to first quote. No credit card.
Track MRNA free See the full squeeze board